Nephrosclerosis: Update on a centenarian

Nephrology Dialysis Transplantation

Volumn 30, Issue 11, 2015, Pages 1833-1841

  Meyrier, Alain ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Ageing; Black race; FSGS; Hypertension; Nephrosclerosis; Renal autoregulation; Renal hypoxia

Indexed keywords

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT;

AGED; AGING; APOL1 GENE; ARTERIAL STIFFNESS; ARTERIOLOSCLEROSIS; AUTOREGULATION; DIAGNOSTIC ERROR; END STAGE RENAL DISEASE; ETHNIC DIFFERENCE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLOMERULOPATHY; HUMAN; HYALINE DEGENERATION; HYPERTENSION; HYPOXIA; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY ISCHEMIA; METABOLIC DISORDER; MYH9 GENE; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; VERY ELDERLY; COMPLICATION; PATHOLOGY; RISK FACTOR;

HUMANS; HYPERTENSION; NEPHROSCLEROSIS; RISK FACTORS;

EID: 84948409718     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu366     Document Type: Review

References (83)

1. Fahr T. Über Nephrosklerose. Virchows Arch (Pathol Anat) 1919; 26: 119-178
2. Volhard F. Die Sklerosen, in Die doppelseitigen hämatogenen Nierenerkrankungen (Brightsche Krankheit). Berlin, Springer Verlag, 1918, p 491
3. Luke RG. Essential hypertension: a renal disease? Hypertension 1993; 21: 380-390
4. Meyrier A, Simon P, Montseny JJ et al. Vascular nephropathies and nephrosclerosis: Epidemiology and pathophysiology. In Grünfeld JP, Bach JF, Kreis H, Maxwell MH (eds). Advances in Nephrology Chicago, Mosby Yearbook Publishers, 1996, 207 pp
5. Meyrier A, Simon P. Nephroangiosclerosis and hypertension: things are not as simple as you might think. Nephrol Dial Transplant. 1996; 11: 2116-2120
6. Meyrier A, Hill GS, Simon P. Ischemic renal diseases: new insights into old entities. Kidney Int 1998; 54: 2-13
7. Hill GS. Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens 2008; 17: 266-270
8. Heptinstall RH. Pathology of the Kidney, 3rd edn. Vol 1, Chapter 5. Little, Brown & Co, 1983, pp. 181-246
9. Bohle A, von Gise H, Mackensen-Haen S et al. The obliteration of the postglomerular capillaries and its influence upon the function of both glomeruli and tubuli. Functional interpretation of morphologic findings. KlinWochenschr 1981; 59: 1043-1051
10. Bohle A, Müller GA, Wehrmann M et al. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int 1997; 49(Suppl 54): S2-S9
11. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20: 1-17
12. Choi YJ, Chakraborty S, Nguyen V et al. Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor. Hum Pathol 2000; 31: 1491-1497
13. Rodriguez-Iturbe B. Renal infiltration of immunocompetent cells: cause and effect of sodium-sensitive hypertension. Clin Exp Nephrol 2010; 14: 105-111
14. Kincaid-Smith P. Vascular lesions associated with idiopathic glomerular lesions. In: Kincaid-Smith P (ed). The kidney. A clinico-pathological study. Blackwell Scientific, Oxford, 1975; 193-202
15. Gallo GR, Feinter JM, Steele JM et al. Role of intrarenal vascular sclerosis in progression of poststreptococcal glomerulonephritis. Clin Nephrol 1980; 13: 49-57
16. Stein-Oakley AN, Maguire JA, Dowling J et al. Altered expression of fibrogenic growth factors in IgA nephropathy and focal and segmental glomerulosclerosis. Kidney Int 1997; 51: 195-204
17. Radford MGJ, Donadio JVJ, Bergstralh EJ et al. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997; 8: 199-207
18. Zeier M, Fehrenbach P, Geberth S et al. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 1992; 42: 1259-1265
19. Tracy RE, Bhandaru SY, Oalmann MC et al. Blood pressure and nephrosclerosis in black and white men and women aged 25-54. Mod Pathol 1991; 4: 602-609
20. Tracy RE. Renovasculopathies of hypertension and the rise of blood pressure with age in blacks and whites. Semin Nephrol 1996; 16: 126-133
21. Tracy RE, Guzman MA, Oalmann MC et al. Nephrosclerosis in three cohorts of Black and White men born 1925 to 1944, 1934 to 1953 and 1943 to 1962. Am J Hypertens 1993; 6: 185-192
22. Tracy RE, Malcom GT, Oalmann MC et al. Renal microvascular features of hypertension in Japan, Guatemala, and USA. Arch Pathol Lab Med 1992; 116: 50-55
23. Griffin SA, Brown WC, MacPherson F et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991; 17: 626-635
24. Johnson RJ, Alpers CE, Yoshimura A et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992; 19: 464-474
25. Smeda JS, Lee RM, Forrest JB. Prenatal and postnatal hydralazine treatment does not prevent renal vessel wall thickening in SHR despite the absence of hypertension. Circ Res 1988; 63: 534-542
26. Krege JH, John SWM, Langenbach LL et al. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 1995; 375: 146-148
27. Kim HS, Krege JH, Kluckman KD et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92: 2735-2739
28. Niimura F, Labosky PA, Kakuchi J et al. Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 1995; 96: 2947-2954
29. Véniant M, Ménard J, Bruneval P et al. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 1996; 98: 1966-1970
30. Armin J. Mechanisms of renal blood flow autoregulation: dynamics and contributions. Am J Physiol Regul Integr Comp Physiol 2007; 292: R1-R17
31. Bidani AK, Schwartz M, Lewis E. Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol 1987; 252: F1003-F1010
32. Bidani AK, Polichnowski AJ, Polichnowski AJ et al. Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens 2013; 22: 1-9
33. Pelayo JC, Westcott JY. Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron. J Clin Invest 1991; 88: 101-105
34. Griffin KA, Picken MM, Bidani AK. Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 1994; 4: 2023-2031
35. Hayashi K, Epstein M, Loutzenhiser R et al. Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangement. J Am Soc Nephr 1992; 2: 1578-1586
36. Imig JD, Passmore JC, Anderson GL et al. Chloride alters blood flow autoregulation in deoxycorticosterone-treated rats. J Lab Clin Med 1993; 121: 608-613
37. Takenaka T, Forster H, De MA et al. Impaired myogenic responsiveness of renal microvessels in Dahl salt-sensitive rats. Circ Res 1992; 71: 471-480
38. Wang X, Ajikobi DO, Slevski FC et al. Impaired myogenic autoregulation in kidneys of Brown-Norway rats. Am J Physiol Renal Physiol 2000; 278: F962-F969
39. Van Dokkum RP, Sun CW, Provoost AP et al. Altered renal hemodynamics and impaired myogenic responses in the fawn-hooded rat. Am J Physiol 1999; 276: R855-R863
40. Kimura K, Tojo A, Hirata Y et al. Morphometric analysis of renal arterioles in subtotally nephrectomized rats. J Lab Clin Med 1993; 122: 273-283
41. Iversen BM, Amann K, Kvam FL et al. Increased glomerular capillary pressure and size mediate glomerulosclerosis in SHR juxtamedullary cortex. Am J Physiol 1998; 274: F365-F373
42. Christensen PK, Hommel EE, Clausen P et al. Impaired autoregulation of the glomerular filtration rate in patients with non-diabetic nephropathies. Kidney Int 1999; 56: 1517-1523
43. Hill GS, Heudes D, Bariéty J. Morphometric study of arterioles and glomeruli in the aging kidney suggests focal loss of autoregulation. Kidney Int 2003; 63: 1027-1036
44. Hill GS, Heudes D, Jacquot C et al. Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int 2006; 69: 823-831
45. Brezis M, Rosen S. Hypoxia of the renal medulla-Its implications for disease. N Engl J Med 1995; 332: 647-655
46. Haase VH. Hypoxia-inducible factor signaling in the development of kidney fibrosis. Fibrogenesis Tissue Repair 2012; 5(Suppl 1): S1-S16
47. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008; 74: 867-872
48. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to chronic renal failure. J Am Soc Nephrol 2006; 17: 17-25
49. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000; 58: 2351-2366
50. Farris AB, Colvin BC. Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens 2012; 21: 289-300
51. Kohno M, Morio T, Ikeda M et al. Angiotensin II stimulates endothelin-I secretion in cultured rat mesangial cells. Kidney Int 1992; 42: 860-866
52. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor β-1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456-461
53. Chan PC, Clavell A, Keiser J et al. Effects of renin-angiotensin system in mediating endothelin-induced renal vasoconstriction: therapeutic implications. J Hypertens 1994; 12: S43-S49
54. Kim S, Ohta K, Hamaguchi A et al. Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int 1994; 46: 1346-1358
55. Hamaguchi A, Kim S, Ohta K et al. Transforming growth factor-β 1 expression and phenotypic modulation in the kidney of hypertensive rats. Hypertension 1995; 26: 199-207
56. Barton M, Tharaux PL. Endothelin and the podocyte. Clin Kidney J 2012; 5: 17-27
57. Higgins DF, Kimura K, Bernhardt WM et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007; 117: 3810-3820
58. Neusser MA, Lindenmeyer MT, Moll AG et al. Human nephrosclerosis triggers a hypoxia-related glomerulopathy. Am J Pathol 2010; 176: 594-607
59. Haase VH. Oxygen regulates epithelial-to-mesenchymal transition: insights into molecular mechanisms and relevance to disease. Kidney Int 2009; 76: 492-499
60. Weisstuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease? Kidney Int 1992; 36(Suppl., May): S33-S37
61. Murea MM, Freedman BI. Essential hypertension and risk of nephropathy: a reappraisal. Curr Opin Nephrol Hypertens 2010; 19: 235-241
62. Zucchelli P, Zuccala A. The diagnostic dilemma of hypertensive nephrosclerosis: the nephrologist's view. Am J Kidney Dis 1993; 21(Suppl 2): 87-91
63. Schlessinger SD, Tankersley MR, Curtis JJ. Clinical documentation of end stage renal disease due to hypertension. Am J Kidney Dis 1994; 23: 655-660
64. Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol 2008; 294: F685-F696
65. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195-2200
66. Grobe JL, Rahmouni K. The adipose/circulating renin-angiotensin system cross-talk enters a new dimension. Hypertension 2012; 60: 1389-1390
67. Yiannikouris F, Gupte M, Putnam K et al. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension 2012; 60: 1524-1530
68. Hsu CY. Does non-malignant hypertension cause renal insufficiency? Evidence-based perspective. Curr Opin Nephrol Hypertens 2002; 11: 267-272
69. Kopp JB. Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder. Curr Opin Nephrol Hypertens 2013; 22: 266-272
70. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845
71. Lipkowitz MS, Freedman BI, Langefeld CD et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013; 83: 114-120
72. Cooper Worobey C, Fisher ND, Cox D et al. Genetic polymorphisms and the risk of accelerated renal function decline in women. PLoS ONE 2009; 4: e4787
73. Scolari F, Izzi C, Ghiggeri GM. Uromodulin: from monogenic to multifactorial diseases. Nephrol Dial Transplant 2015; 30: 1250-1256
74. Liu M, Li Y, Citterio L et al. A functional common polymorphism of the ABCB1 gene is associated with chronic kidney disease and hypertension in Chinese. Am J Hypertens 2013; 26: 1428-1436
75. Holdaas H, Hartmann A, Berg KJ et al. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant 1998; 13: 3096-3102
76. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96: 793-800
77. Bakris GL. Renal effects of calcium antagonists in diabetes mellitus: an overview of studies in animal models and in humans. Am J Hypertens 1991; 4(Suppl:4): 87S-93S
78. Ruggenenti P, Perna A, Benini R et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol 1998; 9: 2096-2101
79. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346: 1145-1151
80. Textor SC, Novick AC, Tarazi RC et al. Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med 1985; 102: 308-314
81. Textor SC. Pathophysiology of renal failure in renovascular disease. Am J Kidney Dis 1994; 24: 642-651
82. Bridoux F, Hazzan M, Pallot JL et al. Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis. Nephrol Dial Transplant 1992; 7: 100-104
83. Ruzicka M, Quinn RR, McFarlane P et al. Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for the management of blood pressure in CKD. Am J Kidney Dis 2014; 63: 869-887